Lynch Syndrome X-Talk of Enteral Mucosa With Immune System (NCT06708429)
Impact of Immune-surveillance on the Development of Colorectal Cancer in Patients With Lynch Syndrome
🩺 Plain-English Summary (8th-Grade Level)
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM. Despite adherence to cancer surveillance programs, many patients still develop colorectal cancer and endometrial cancer. The Prospective Lynch Syndrome Database (PLSD) suggests that more frequent surveillance intervals do not significantly improve cancer risk reduction. The PLSD also revealed that the incidence of colorectal cancer in MLH1 and MSH2 carriers was even higher than previously expected, reaching as high as 41-36% among MLH1 carriers, regardless of ethnic background. The development of colorectal cancer despite surveillance is an unresolved question. Therefore, there is an unmet need for effective cancer prevention strategies.
Who can join: Review the eligibility criteria below.
Location: Beckman Research Institute at City of Hope — Monrovia, California
Age range: 18 Years
🧪 Interventions in This Study
- LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System) (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Beckman Research Institute at City of Hope — Monrovia, California
- Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital — Milan, Lombardy
- Dipartimento di Chirurgia Oncologica e Dipartimento di Oncologia Sperimentale Istituto Nazionale Tumori — Milan, MI
- Dipartimento di controllo qualità e rischio chimico biologico, AOOR Villa Sofia Cervello — Palermo, PM
- Chirurgia Generale, Azienda Ospedaliero Universitaria di Cagliari — Cagliari,
📞 Contact the Study Coordinator
Phone: (022) 643-6303
Email: cavestro.giuliamartina@hsr.it
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lynch Syndrome
- Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes — New York, New York
- Multi-Organ Screening Recommendations in Patients With Lynch Syndrome — Basking Ridge, New Jersey
- Overcoming Barriers to Uptake of Cascade Screening — Chapel Hill, North Carolina
- A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule — Boston, Massachusetts
- Lynch Syndrome Integrative Epidemiology and Genetics — Aurora, Colorado
Explore by condition: All Lynch Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.